GLP-1 Before Surgery: What to Tell Your Doctor & Anesthesiologist [2026]

1. Overview: Why GLP-1 Medications Matter for Surgery

The rapid growth of GLP-1 receptor agonist prescribing - with an estimated 6-9 million Americans using medications like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Victoza, Saxenda) as of 2026 - has created a new and critically important intersection between medication management and surgical safety. Anesthesiologists, surgeons, and other perioperative care providers now encounter patients on these medications with increasing frequency, and the implications for surgical planning are significant.

The core concern centers on a fundamental pharmacological effect of all GLP-1 receptor agonists: delayed gastric emptying. While this effect is therapeutically beneficial (it contributes to appetite suppression and improved blood sugar control by slowing the rate at which nutrients enter the small intestine), it creates a specific hazard during anesthesia. When a patient goes under general anesthesia, the protective reflexes that normally prevent stomach contents from entering the lungs - coughing, swallowing, the gag reflex - are suppressed. If the stomach contains food or liquid because gastric emptying has been slowed by GLP-1 medication, there is an increased risk that this material could flow backward into the esophagus and be inhaled into the lungs, a complication known as pulmonary aspiration.

Pulmonary aspiration is one of the most feared complications in anesthesiology. Despite being relatively rare in modern practice (occurring in approximately 1-4 per 10,000 general anesthetics in the general population), it carries significant morbidity and mortality. Aspiration of acidic stomach contents can cause severe chemical injury to the lung tissue (aspiration pneumonitis), bacterial infection (aspiration pneumonia), acute respiratory distress syndrome (ARDS), and death. The recognition that GLP-1 medications could increase this already-serious risk prompted the American Society of Anesthesiologists to issue specific guidance in 2023, with subsequent updates that have become the standard of care for perioperative GLP-1 management.

The Scale of the Problem

The intersection of GLP-1 use and surgical need is enormous. Approximately 50 million inpatient surgical procedures and 30 million outpatient procedures are performed annually in the United States. With 6-9 million Americans now on GLP-1 medications, a substantial proportion of surgical patients will be taking these drugs. In some surgical populations - particularly bariatric surgery candidates, orthopedic joint replacement patients (where obesity is a major risk factor), and cardiac surgery patients (where diabetes is prevalent) - the proportion of patients on GLP-1 therapy may be 15-30% or higher.

This scale means that perioperative GLP-1 management is not a niche concern but a mainstream issue that every surgical facility and anesthesia practice must address through standardized protocols. Patients bear equal responsibility: disclosing GLP-1 use to their surgical team, understanding why and when to stop the medication, and following the pre-operative preparation instructions specific to their situation.

What This Guide Covers

Guide walks patients through every aspect of managing GLP-1 medications around surgery. We will explain the science behind delayed gastric emptying and aspiration risk, detail the ASA guidelines with practical interpretation, provide medication-specific stop timelines for every approved GLP-1 agent, offer a communication checklist for surgical team interactions, cover special situations including emergency surgery, bariatric surgery, dental procedures, and endoscopy, and answer the most frequently asked questions from patients navigating this process.

Our goal is to help patients with the knowledge and tools to be informed participants in their own surgical safety. GLP-1 medications and surgery can coexist safely when properly managed - the key is planning, communication, and following evidence-based guidelines.

2. Understanding Delayed Gastric Emptying and Surgical Risk

To understand why GLP-1 medications pose a concern before surgery, it helps to first understand normal gastric physiology and how these medications alter it. The stomach serves as both a reservoir and a processing plant for food. After eating, the stomach stores food, mixes it with gastric acid and digestive enzymes, and gradually releases the partially digested material (chyme) into the small intestine through the pyloric sphincter. This process - gastric emptying - is normally tightly regulated by a complex interplay of neural, hormonal, and mechanical signals.

Normal Gastric Emptying

In a healthy adult who is not taking any medications that affect GI motility, the stomach empties approximately 50% of its solid food content within 2-3 hours and is essentially empty of solids within 4-6 hours after a standard meal. Liquids empty more rapidly, with 50% clearance in approximately 20-30 minutes and essentially complete clearance within 1-2 hours for clear fluids. These normal emptying rates are the basis for standard pre-operative fasting guidelines: nothing to eat for 6-8 hours before surgery, and clear liquids permitted up to 2 hours before.

The gastric emptying rate is controlled by several factors. The volume and composition of the meal matter - high-fat and high-calorie meals empty more slowly. Neural signals from the stomach (stretch receptors detecting fullness) and the duodenum (nutrient receptors detecting fat, protein, and acidity) modulate the rate. Hormonal signals, including GLP-1 released from intestinal L-cells after eating, provide feedback to slow emptying when the small intestine is already processing nutrients.

How GLP-1 Receptor Agonists Delay Gastric Emptying

GLP-1 receptor agonists delay gastric emptying through multiple mechanisms. At the central nervous system level, GLP-1 receptor activation in the brainstem (particularly the nucleus tractus solitarius and the area postrema) generates inhibitory signals that slow gastric motility. Peripherally, GLP-1 receptor activation on vagal afferent nerves in the gut wall transmits signals that suppress gastric motor activity. Additionally, GLP-1 receptor activation may directly reduce the release of motilin and other prokinetic gut hormones while enhancing the release of inhibitory signals like peptide YY.

The net effect is that patients on GLP-1 receptor agonists have measurably slower gastric emptying compared to untreated individuals. Gastric emptying studies (scintigraphy) have shown that semaglutide increases the gastric half-emptying time by approximately 30-60 minutes for solid foods, meaning that food remains in the stomach longer after a meal. While this degree of delay is clinically mild compared to true gastroparesis (where gastric emptying time can be hours to days longer than normal), it is sufficient to alter the risk calculus for anesthesia.

The Variability Problem

One of the most challenging aspects of GLP-1 delayed gastric emptying from an anesthesia perspective is its variability. Not all patients on GLP-1 medications experience the same degree of gastric slowing. Factors that influence individual gastric emptying rates include the specific GLP-1 medication and dose (higher doses generally cause more delay), the duration of therapy (some studies suggest the degree of delayed emptying attenuates over months of continuous use), individual patient factors (baseline gastric motility, autonomic neuropathy, concomitant medications), and the timing of the last dose relative to the last meal.

This variability means that a one-size-fits-all approach to GLP-1 management before surgery is imperfect. Some patients who stopped their weekly semaglutide 7 days before surgery may still have significant delayed emptying, while others may have essentially normal gastric function. Conversely, some patients may have clinically insignificant delayed emptying even with recent GLP-1 dosing. This uncertainty is why the ASA guidelines include provisions for gastric ultrasound assessment and clinical symptom evaluation in addition to fixed medication hold timelines.

Gastric Emptying vs. True Gastroparesis

It is important to distinguish between GLP-1-induced delayed gastric emptying and true gastroparesis. Gastroparesis is a chronic condition characterized by severely impaired gastric motility, typically defined as greater than 10% gastric retention at 4 hours on a standardized scintigraphy study. GLP-1-induced delayed emptying is generally milder, dose-dependent, and at least partially reversible upon drug discontinuation.

However, some patients on GLP-1 medications - particularly those with pre-existing risk factors for gastroparesis (long-standing diabetes with autonomic neuropathy, prior gastric surgery, hypothyroidism) - may develop gastroparesis-like symptoms that are more severe and persistent. These patients represent a higher-risk group from an anesthesia perspective and may require more extended medication holds and more aggressive pre-operative gastric assessment.

Post-marketing reports to the FDA have included cases of patients on GLP-1 medications presenting for surgery with retained solid food in the stomach despite following standard pre-operative fasting instructions. While these reports are anecdotal, they highlight the clinical reality that standard fasting times may be insufficient for some GLP-1 patients - a concern that drove the ASA to issue its guidance.

3. Aspiration Risk During Anesthesia: A Deep Dive

Pulmonary aspiration - the inhalation of stomach contents into the lungs - is a well-characterized and potentially devastating complication of general anesthesia. Understanding this risk in detail helps patients appreciate why their surgical team takes GLP-1 medication management so seriously.

How Aspiration Occurs During Anesthesia

Under normal waking conditions, several protective mechanisms prevent stomach contents from entering the lungs. The lower esophageal sphincter (LES) acts as a barrier between the stomach and esophagus. The laryngeal reflexes (coughing and gag reflex) protect the airway entrance. And conscious swallowing helps clear any material that reaches the throat. During general anesthesia, all of these protective mechanisms are compromised simultaneously.

General anesthetic agents relax the LES, reducing its barrier function. Neuromuscular blocking agents (muscle relaxants used to help with intubation and surgery) paralyze the muscles of the larynx and pharynx that normally protect the airway. Deep sedation or anesthesia suppresses the cough reflex and gag reflex. And the patient is unconscious and unable to swallow intentionally. In this state, if the stomach contains food, liquid, or even excess gastric secretions, this material can passively regurgitate into the esophagus, flow into the pharynx, and be aspirated through the open or partially protected airway into the trachea and lungs.

The Consequences of Aspiration

The severity of aspiration depends on the volume and nature of the aspirated material. Aspiration of acidic gastric fluid (pH below 2.5) causes chemical pneumonitis - a direct acid burn of the lung tissue that triggers an intense inflammatory response, pulmonary edema (fluid accumulation in the lungs), and impaired gas exchange. This condition was first described by Dr. Curtis Mendelson in 1946 and is sometimes called Mendelson syndrome.

Aspiration of solid food particles causes mechanical airway obstruction, which can be immediately life-threatening if large pieces occlude the trachea or main bronchi. Even smaller food particles can obstruct segmental bronchi, causing distal lung collapse (atelectasis) and creating a nidus for subsequent infection.

Aspiration pneumonia develops when bacteria from the oropharynx or stomach are introduced into the lower respiratory tract along with the aspirated material. This infection can range from mild community-acquired pneumonia to severe necrotizing pneumonia requiring intensive care.

In the most severe cases, aspiration leads to acute respiratory distress syndrome (ARDS), a life-threatening condition characterized by widespread inflammation in the lungs, severe hypoxemia (low blood oxygen), and the need for mechanical ventilation. ARDS carries a mortality rate of approximately 30-40% and can result in prolonged ICU stays and long-term lung damage in survivors.

Aspiration Risk Factors in the General Population

Even without GLP-1 medications, certain patient characteristics increase aspiration risk during anesthesia. These include obesity (increased intra-abdominal pressure pushes stomach contents upward), gastroesophageal reflux disease (GERD) (weakened LES allows easier regurgitation), diabetes with gastroparesis (delayed emptying retains stomach contents), pregnancy (hormonal and mechanical effects on gastric function), hiatal hernia (anatomic disruption of the anti-reflux barrier), and emergency surgery (no time for proper fasting). Many GLP-1 patients already have one or more of these risk factors (particularly obesity and diabetes), making the additive effect of GLP-1 delayed gastric emptying particularly concerning.

The GLP-1 Incremental Risk

Quantifying the exact incremental aspiration risk from GLP-1 medications is difficult because the background rate is already low and large prospective studies specifically measuring aspiration events in GLP-1 patients have not been conducted. However, several lines of evidence suggest the risk is clinically meaningful.

Case reports and small case series have documented patients on GLP-1 medications who presented for surgery with significant retained gastric contents despite standard fasting. Some of these cases resulted in aspiration events during intubation or emergence from anesthesia. A retrospective analysis published in 2023 found that patients on GLP-1 medications had significantly higher rates of residual gastric contents on pre-operative ultrasound compared to matched controls, even after following standard fasting protocols.

The anesthesia community response - issuing formal guidelines through the ASA - reflects the consensus that the risk is sufficient to warrant specific management protocols. While the absolute risk of aspiration remains low even in GLP-1 patients, the potential consequences are severe enough that precautionary measures are strongly justified.

4. ASA 2023 Guidelines: What They Say and What They Mean

In June 2023, the American Society of Anesthesiologists issued a consensus-based guidance document titled "Considerations for the Pre-operative Management of Patients on Glucagon-Like Peptide-1 Receptor Agonists." This document has become the primary reference for perioperative GLP-1 management in the United States and has influenced similar guidance from anesthesiology societies worldwide. Understanding both the letter and the spirit of these guidelines is essential for patients and providers.

Key Recommendations

The ASA guidance contains several core recommendations. First, for elective procedures, GLP-1 receptor agonists administered weekly (semaglutide, dulaglutide, exenatide extended-release, tirzepatide) should be held on the day of the scheduled dose if the patient is due for the injection within the week before surgery. In practical terms, this means the last dose should be taken at least 7 days before the procedure. Second, for GLP-1 medications administered daily (liraglutide, oral semaglutide, exenatide immediate-release), the medication should be held on the day of surgery (essentially a 24-hour hold). Third, the guidelines emphasize that holding the medication alone may not be sufficient. If the patient has GI symptoms at the time of the pre-operative assessment - including nausea, vomiting, dyspepsia, abdominal distension, or bloating - the patient should be considered at increased risk for aspiration regardless of when the last GLP-1 dose was taken, and appropriate precautions should be taken.

The ASA also recommends that anesthesiologists consider point-of-care gastric ultrasound for GLP-1 patients presenting for surgery to directly assess the volume and nature of gastric contents. If significant solid or liquid is found in the stomach, the procedure may be delayed (if elective) or the anesthesia team may employ full-stomach precautions including rapid sequence intubation.

What "Consensus-Based" Means

It is important for patients to understand that the ASA guidance is described as "consensus-based" rather than "evidence-based." This distinction is meaningful. A true evidence-based guideline would be supported by randomized controlled trials comparing different GLP-1 management strategies and measuring aspiration outcomes. No such trials exist, and conducting them would be extremely difficult given the rarity of aspiration events. Instead, the ASA assembled a panel of experts who reviewed the available pharmacological data, case reports, and clinical experience, and reached consensus on reasonable precautionary measures.

The consensus-based nature of the guidelines means that there is reasonable room for clinical judgment in individual cases. Some anesthesiologists may be more conservative (recommending longer holds, like 2-3 weeks), while others may be more liberal (proceeding with 7-day holds as sufficient in the absence of GI symptoms). Neither approach is definitively right or wrong based on current evidence - the guidelines provide a framework, but individual patient assessment remains essential.

Evolution of the Guidelines

The ASA guidance has been updated since its initial 2023 release to incorporate emerging evidence and clinical experience. Key evolutionary changes include greater emphasis on gastric ultrasound as a decision-making tool, recognition that some patients may have persistent delayed gastric emptying even after holding GLP-1 medications for the recommended period, clarification that the guidelines apply to all procedures requiring general anesthesia or deep sedation (not just "surgery"), and expanded discussion of the balance between aspiration risk and the risks of delaying necessary surgery.

Similar guidance has been issued by anesthesiology societies in Canada, the United Kingdom, Australia, and Europe, with generally consistent recommendations. The global consensus reinforces the significance of this issue and the importance of standardized approaches to GLP-1 perioperative management.

5. When to Stop Each GLP-1 Medication: Specific Timelines

One of the most practical questions patients face is exactly when to stop their specific GLP-1 medication before a scheduled procedure. This section provides medication-specific guidance based on the ASA recommendations, pharmacokinetic properties, and clinical practice patterns.

Practical Timing Examples

Example 1 - Semaglutide (Ozempic/Wegovy), weekly injection on Wednesdays, surgery scheduled for Thursday: The patient should skip their Wednesday injection the week before surgery. Their last dose would be the Wednesday before that, giving them 8 days medication-free by the time of surgery. This exceeds the 7-day minimum and is ideal timing.

Example 2 - Tirzepatide (Mounjaro), weekly injection on Fridays, surgery scheduled for Monday: The patient should skip their Friday injection the week before surgery. Their last dose was the Friday prior to that, giving them 10 days medication-free. If the patient had already taken their Friday dose when surgery was scheduled, they would have only 3 days - insufficient by ASA guidelines. In this case, either reschedule surgery or employ full-stomach precautions.

Example 3 - Liraglutide (Saxenda), daily injection, surgery scheduled for Tuesday morning: The patient should not take their Monday evening or Tuesday morning dose. Their last dose would be Monday morning at the latest, giving approximately 24 hours medication-free. Some providers recommend stopping 48-72 hours before for additional safety margin.

Example 4 - Oral semaglutide (Rybelsus), daily tablet, surgery scheduled for Wednesday morning: The patient should not take their Wednesday morning dose. Their last dose would be Tuesday morning, providing approximately 24 hours medication-free. However, since oral semaglutide achieves the same systemic drug levels as injectable semaglutide (and has the same half-life), some providers recommend a longer hold similar to the injectable formulation.

The Debate: 7 Days vs. Longer Holds

There is ongoing debate within the anesthesiology community about whether the ASA 7-day hold for weekly GLP-1 injections is sufficient. Arguments for a longer hold (2-3 weeks) include the fact that semaglutide half-life of 7 days means that after 7 days, approximately 50% of the drug is still active; the gastric emptying effect may not resolve proportionally to drug clearance; individual variation in drug metabolism means some patients may have higher-than-expected drug levels at 7 days; and the conservative approach minimizes a potentially catastrophic complication with minimal downside.

Arguments against extending the hold beyond 7 days include: longer holds increase the period of uncontrolled diabetes or weight management; the gastric emptying effect of GLP-1 medications attenuates with continued use and may not be proportional to drug levels; gastric ultrasound can assess the actual gastric status regardless of hold duration; and delaying surgery for additional washout time has its own risks (cancer progression, pain, functional decline).

In practice, many anesthesiologists have adopted a pragmatic middle ground: a 7-day hold is the minimum, with additional assessment (GI symptoms, gastric ultrasound) on the day of surgery to determine whether the patient is actually safe to proceed. This individualized approach balances aspiration risk reduction with the risks of delayed surgery and uncontrolled metabolic disease.

6. What to Tell Your Surgical Team: A Communication Checklist

Clear and complete communication with your surgical team about GLP-1 medication use is essential for safe surgical planning. This section provides a structured checklist that patients should follow when interacting with their surgical and anesthesia providers.

Information to Share at the Pre-Operative Consultation

Who Needs to Know

Multiple members of the surgical team need to be aware of your GLP-1 use, and you should not assume that information shared with one team member will automatically be communicated to others. Tell your primary care physician or the provider who prescribes your GLP-1 medication at the earliest opportunity when surgery is being planned - they can advise on when to stop and how to manage your diabetes or weight during the medication-free period. Tell your surgeon at the pre-operative consultation - they need to know for surgical planning and can coordinate with the anesthesia team. Tell the pre-operative assessment nurse or physician who evaluates you before surgery (often at a separate pre-op appointment or phone call) - they are specifically tasked with identifying medication and anesthesia risk factors. Tell the anesthesiologist on the day of surgery - even if you have told everyone else, confirm directly with the person who will be managing your airway. Tell the pre-operative holding area nurse on the day of surgery - they will document this in your chart and can relay the information to the anesthesia team.

What to Ask Your Surgical Team

In addition to providing information, patients should actively ask questions about their perioperative GLP-1 management. Important questions to ask include: When exactly should I stop my GLP-1 medication? Do I need to stop any other diabetes medications? Should I modify my diet in the days before surgery (e.g., switch to liquids for 24-48 hours)? Will I need a gastric ultrasound on the day of surgery? How will my blood sugar be managed during the medication-free period and during surgery? What type of anesthesia will be used, and will it be modified because of my GLP-1 use? When can I restart my GLP-1 medication after surgery? Should I restart at my current dose or retitrate from a lower dose?

Documentation Is Key

Patients should document their GLP-1 usage and discontinuation timeline in writing. Consider keeping a medication diary that records the date and time of every GLP-1 injection for the 4-6 weeks before surgery. This provides an objective record that can be shared with the surgical team and eliminates any uncertainty about when the last dose was taken. Some patients find it helpful to take a photo of their injection pen with the date on their phone as a simple documentation method.

7. Pre-Operative Assessment for GLP-1 Patients

The pre-operative assessment for patients on GLP-1 medications includes all standard pre-surgical evaluation components plus specific assessments related to GLP-1 use. Understanding what to expect during this assessment helps patients prepare and participate actively in their care.

Standard Pre-Operative Evaluation

Every surgical patient undergoes a pre-operative evaluation that includes a comprehensive medical history review, physical examination, laboratory tests (blood work including complete blood count, basic metabolic panel, coagulation studies, and type and screen if blood transfusion is possible), an electrocardiogram (ECG) for patients with cardiovascular risk factors, and a review of medications with specific instructions about which to take and which to hold on the morning of surgery.

Additional GLP-1-Specific Assessments

GI symptom screening: The pre-operative team should specifically ask about current GI symptoms including nausea, vomiting, bloating, early satiety, abdominal pain, and changes in bowel habits. The presence of these symptoms suggests ongoing significant delayed gastric emptying and may influence anesthetic management decisions.

Gastric ultrasound: Point-of-care gastric ultrasound is increasingly used in GLP-1 patients presenting for surgery. This non-invasive bedside assessment takes approximately 2-3 minutes and can determine whether the stomach contains clear liquid, thick liquid, or solid food, and can estimate the volume of gastric contents. The assessment is performed with the patient in the right lateral decubitus position, with the ultrasound probe placed in the epigastric area. An empty antrum (the distal portion of the stomach) suggests low aspiration risk, while the presence of solid contents or large fluid volumes indicates higher risk.

Gastric ultrasound is not universally available or universally performed, but its use is growing rapidly. Patients can ask their anesthesiologist whether gastric ultrasound will be performed and, if significant contents are found, what the plan will be (delay surgery, proceed with RSI, or decompress the stomach with a nasogastric tube).

Blood glucose assessment: For diabetic patients, fasting blood glucose should be checked on the morning of surgery. The period of GLP-1 medication withdrawal may have allowed blood sugar levels to rise, and the surgical team needs to know the current glucose level to plan intraoperative insulin management. Target blood glucose ranges during surgery are typically 140-180 mg/dL, and insulin infusion protocols are available for patients with elevated levels.

Nutritional status assessment: Patients who have experienced significant weight loss on GLP-1 therapy may have nutritional deficiencies that affect surgical healing and anesthesia tolerance. Albumin and pre-albumin levels, if not recently checked, may be useful markers of nutritional status. Significant hypoalbuminemia (albumin below 3.5 g/dL) is associated with increased surgical complications and poor wound healing.

8. Fasting Guidelines: NPO Considerations for GLP-1 Patients

Pre-operative fasting (NPO, from the Latin "nil per os" meaning nothing by mouth) is a fundamental safety measure designed to minimize gastric volume at the time of anesthesia induction. Standard fasting guidelines have been established based on normal gastric physiology, and GLP-1 use introduces important nuances that patients should understand.

Standard NPO Guidelines (Non-GLP-1 Patients)

For the general population, the ASA pre-operative fasting guidelines recommend: no solid food for at least 6-8 hours before anesthesia (practically, "nothing to eat after midnight" for morning cases); clear liquids (water, black coffee, clear tea, apple juice, clear broth) may be consumed up to 2 hours before anesthesia; fried or fatty foods may require 8 or more hours of fasting due to slower gastric emptying; and breast milk, infant formula, and non-human milk have specific timelines for pediatric patients.

Modified Fasting Considerations for GLP-1 Patients

The ASA 2023 guidance does not specify extended fasting times for GLP-1 patients beyond the standard recommendations, provided the medication has been held for the recommended duration and the patient is asymptomatic. However, many anesthesiologists and institutions have adopted modified fasting approaches for GLP-1 patients that go beyond the standard guidelines.

Common modifications include recommending a liquid-only or soft food diet for 24-48 hours before surgery (rather than normal eating up to the standard NPO cutoff), extending the solid food fasting period to 12 hours or longer, being more restrictive about "clear liquid" composition (avoiding any caloric clear liquids), and considering a full liquid diet for the day before surgery similar to colonoscopy preparation.

The rationale for these modifications is that even with a 7-day or longer GLP-1 hold, some residual delayed gastric emptying effect may persist, and starting the fasting period with less solid food in the stomach provides an additional safety margin. A patient who ate a large, fatty dinner the night before surgery may still have significant gastric contents the following morning, even without GLP-1 medications. Adding GLP-1 residual effects to this scenario could result in unacceptably high residual gastric volume.

The Role of Gastric Ultrasound in Fasting Decision-Making

Point-of-care gastric ultrasound is increasingly being used as a real-time decision-making tool for GLP-1 patients on the day of surgery. Rather than relying solely on medication hold times and symptom assessment, the anesthesiologist can directly visualize the stomach contents and make an informed decision.

If gastric ultrasound shows an empty stomach or a small volume of clear liquid (less than 1.5 mL/kg body weight), the patient can proceed with standard anesthesia induction. This finding provides direct evidence that the patient is at low risk for aspiration, regardless of their GLP-1 medication history. If gastric ultrasound shows thick liquid or solid food, the anesthesiologist may choose to delay the procedure (for elective cases), proceed with rapid sequence intubation, or attempt to decompress the stomach with a nasogastric tube before proceeding.

The increasing availability and use of gastric ultrasound may eventually shift the perioperative management of GLP-1 patients from a time-based approach (hold for X days) to an assessment-based approach (check the stomach on the day of surgery), which would be more individualized and potentially more reliable.

Understanding the Difference Between Elective and Urgent Surgery Timelines

One of the most important distinctions for patients on GLP-1 medications to understand is the difference between elective, urgent, and emergent surgical procedures, because the approach to medication management differs significantly depending on how much advance notice you have.

Elective surgeries are planned procedures that are scheduled weeks or months in advance. These include joint replacements, hernia repairs, cosmetic procedures, bariatric surgery, and many other operations that are important but not time-sensitive. For elective surgery, you typically have plenty of time to coordinate with your prescriber about stopping your GLP-1 medication at the appropriate interval before the procedure. This is the ideal scenario and allows for the safest possible perioperative management.

Urgent surgeries need to happen within days to a couple of weeks but are not immediately life-threatening. Examples might include a gallbladder removal for recurrent biliary colic, removal of a suspicious mass that needs prompt biopsy, or a fracture repair that can wait a few days but should not be delayed indefinitely. In these situations, there may be some time to hold your GLP-1 medication, but the hold period may be shorter than the ideal recommendation. Your surgical and anesthesia team will weigh the risks of proceeding with potential residual gastric effects against the risks of delaying the procedure.

Emergent surgeries must happen immediately or within hours to save life or limb. Appendicitis, bowel obstruction, trauma, and emergency cardiac procedures fall into this category. In these situations, there is no time to wait for GLP-1 medication effects to wear off, and the anesthesia team will use protective techniques such as rapid sequence intubation to minimize aspiration risk regardless of medication status. If you are taken to the emergency department and surgery is needed, the most important thing you can do is inform the medical team that you take a GLP-1 medication and tell them when your last dose was.

Carrying a medical alert card in your wallet or using a medical identification app on your phone that lists your GLP-1 medication, dose, and last injection date can be invaluable in emergency situations when you may not be able to communicate this information yourself. This simple precaution takes only a few minutes to set up but could make a meaningful difference in your surgical care if an unexpected procedure becomes necessary.

For patients who know they have an upcoming surgery of any type, the best approach is always to communicate early and often with both your GLP-1 prescriber and your surgical team. The earlier these providers can coordinate, the more options they have for optimizing your care and minimizing risk.

9. Emergency Surgery Considerations

Emergency surgery presents a fundamentally different situation from elective surgery because there is no opportunity to hold GLP-1 medications in advance. Patients on GLP-1 medications who require emergency surgical intervention will be managed using established full-stomach protocols that anesthesiologists routinely employ for other high-risk groups.

Emergency Surgery Principles for GLP-1 Patients

The overarching principle is that no necessary surgery should ever be delayed solely because of GLP-1 medication use. Life-threatening conditions - acute appendicitis, bowel obstruction, internal bleeding, ruptured aortic aneurysm, compound fractures, and other surgical emergencies - require immediate intervention regardless of the patient medication profile. Anesthesiologists are trained to manage full-stomach patients safely, and the techniques used for GLP-1 patients in emergency situations are the same ones used for other full-stomach scenarios (pregnant patients, trauma patients, patients with bowel obstruction).

Key emergency management techniques include rapid sequence intubation (RSI), which involves pre-oxygenation followed by simultaneous administration of an induction agent and a fast-acting neuromuscular blocker, with immediate endotracheal intubation without positive-pressure mask ventilation (which could inflate the stomach and increase regurgitation risk). Cricoid pressure (Sellick maneuver) may be applied to compress the esophagus and prevent passive regurgitation during the intubation period, though the evidence for its effectiveness is debated. Nasogastric or orogastric tube placement can be used to decompress the stomach before induction if time permits, though this is not always feasible or effective for solid stomach contents. Post-intubation suctioning of the airway confirms that no aspiration occurred during the intubation process.

What Patients Should Do in Emergency Situations

If you are on a GLP-1 medication and face an emergency that may require surgery, the most important thing you can do is inform the emergency medical team about your medication. Tell the paramedics, the emergency room physician, the surgeon, and the anesthesiologist about your GLP-1 medication, the dose, and when you last took it. If you are unable to communicate (due to injury, altered consciousness, or other reasons), having this information accessible is valuable. Consider wearing a medical identification bracelet or carrying a medical alert card that lists your GLP-1 medication, keeping an updated medication list in your phone or wallet, and ensuring that your emergency contacts know about your medication list and can relay this information to the medical team.

10. Blood Sugar Management in the Perioperative Period

For patients with type 2 diabetes, stopping a GLP-1 medication before surgery creates a gap in glucose control that needs to be managed. Perioperative blood sugar management is important because both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar) increase surgical complications, impair wound healing, and worsen outcomes.

The Impact of GLP-1 Withdrawal on Glucose Control

When a weekly GLP-1 injection like semaglutide is held for 7 or more days before surgery, the glucose-lowering effect gradually wanes over the hold period. Patients may notice their fasting blood glucose levels rising by day 4-5 after the missed dose, with levels potentially reaching pre-treatment values by day 7-10. The magnitude of this glucose rise depends on the patient baseline diabetes severity, HbA1c level, and whether other diabetes medications are continued.

For patients with mild type 2 diabetes controlled primarily by the GLP-1 medication (with or without metformin), the glucose rise may be modest and manageable. For patients with more severe diabetes requiring multiple medications including insulin, the loss of the GLP-1 component can cause significant hyperglycemia that requires temporary treatment adjustments.

Perioperative Glucose Management Strategies

Your provider may implement one or more of the following strategies to manage blood sugar during the GLP-1 hold period. Maintaining other diabetes medications (metformin, SGLT2 inhibitors, DPP-4 inhibitors) during the hold period provides some ongoing glucose control, though metformin is typically held 24-48 hours before surgery and SGLT2 inhibitors are held 3-4 days before surgery per separate guidelines. Temporary sliding-scale insulin may be prescribed for the perioperative period, with the patient checking blood sugar 2-4 times daily and taking correction doses of rapid-acting insulin if levels exceed target. Temporary basal insulin (such as insulin glargine or detemir) may be started if significant hyperglycemia develops during the hold period. Intraoperatively, the anesthesia team will monitor blood glucose and administer intravenous insulin as needed to maintain levels in the target range of 140-180 mg/dL.

Post-Operative Glucose Management

After surgery, glucose management continues to be important during the period before GLP-1 therapy can be resumed. The surgical stress response (cortisol, epinephrine release) typically causes hyperglycemia for 24-72 hours after major surgery, which may compound the effect of GLP-1 withdrawal. Patients may need continued insulin coverage until their GLP-1 medication is restarted and has reached therapeutic levels (typically 3-5 days after the first post-operative dose for weekly injections).

Good glycemic control in the post-operative period is particularly important for wound healing. Hyperglycemia impairs neutrophil function (white blood cells that fight infection), reduces collagen synthesis (needed for tissue repair), and increases the risk of surgical site infections. Maintaining blood glucose below 180 mg/dL in the post-operative period is a well-established quality metric for surgical care.

11. Surgery Types and GLP-1 Management: A Comprehensive Guide

The approach to GLP-1 management varies somewhat depending on the type of surgery, the anesthesia technique used, and the overall risk profile. This section provides guidance for common surgical scenarios that GLP-1 patients may encounter.

Regional Anesthesia: A Potential Alternative

One important consideration for GLP-1 patients is whether the planned procedure can be performed under regional anesthesia (spinal, epidural, or nerve block) rather than general anesthesia. Regional techniques do not suppress the airway protective reflexes, which means the aspiration risk associated with a full stomach is essentially eliminated. This makes regional anesthesia an attractive option for GLP-1 patients when the surgical procedure is amenable to it.

Procedures commonly performed under regional anesthesia include knee and hip replacements (spinal or epidural), lower extremity surgery (spinal, epidural, or nerve blocks), hand and arm surgery (regional nerve blocks), cesarean delivery (spinal), and some lower abdominal procedures (epidural). Patients can ask their surgeon and anesthesiologist whether regional anesthesia is an option for their procedure, noting that they are on a GLP-1 medication and would prefer to avoid general anesthesia if possible.

However, regional anesthesia is not always feasible or preferable. Some procedures require general anesthesia for surgical access or patient comfort. Some patients have contraindications to regional techniques (blood thinning medications, spinal abnormalities, patient preference). And regional blocks can fail or be inadequate, potentially requiring conversion to general anesthesia during the procedure - in which case, full-stomach precautions would need to be implemented urgently.

Post-Operative Nausea and Vomiting (PONV) Considerations

Patients who take GLP-1 medications may have an increased baseline risk of post-operative nausea and vomiting, commonly known as PONV. This is because GLP-1 receptor agonists can slow gastric motility and affect the chemoreceptor trigger zone in the brain, which plays a role in the sensation of nausea. Even after stopping the medication before surgery, residual effects on gastric motility may persist for several days beyond the last dose.

PONV is already one of the most common complications after general anesthesia, affecting roughly 30 percent of all surgical patients and up to 80 percent of high-risk patients. Risk factors that are already well established include being female, having a history of motion sickness or prior PONV, not smoking, and the use of opioid pain medications after surgery. When GLP-1 use is added to these existing risk factors, the overall PONV risk may be higher than average.

Anesthesia providers can take several steps to reduce PONV risk in GLP-1 patients. These may include using a multimodal anti-emetic approach with two or more anti-nausea medications given before and during surgery, minimizing the use of volatile anesthetic gases in favor of total intravenous anesthesia (TIVA) with propofol, reducing opioid use during and after surgery through regional nerve blocks and non-opioid pain medications, and ensuring adequate hydration before and during the procedure.

As a patient, you can help reduce your PONV risk by following all fasting instructions carefully, staying well-hydrated in the days leading up to surgery, discussing your GLP-1 medication history with your anesthesia provider so they can plan accordingly, and asking about preventive anti-nausea medication. If you have a history of severe nausea with your GLP-1 medication or with previous surgeries, make sure your medical team is aware of this before your procedure.

After surgery, if you experience prolonged nausea or vomiting that prevents you from eating or drinking, contact your surgical team promptly. Persistent PONV can delay recovery, increase the risk of dehydration, and complicate the resumption of oral medications including your GLP-1 therapy.

It is also helpful to know that certain types of surgery are associated with higher PONV rates regardless of GLP-1 use. Abdominal surgeries, gynecological procedures, ear and eye surgeries, and laparoscopic operations tend to cause more post-operative nausea than procedures on the extremities or superficial tissues. If you are scheduled for a procedure that already carries a higher baseline PONV risk, the combination with recent GLP-1 use makes proactive anti-nausea management even more important. Do not hesitate to ask your anesthesia provider what their specific plan is for preventing PONV in your individual case, and let them know if you have had any difficulty with nausea during your GLP-1 treatment or with previous surgical procedures.

12. Anesthesia Techniques for GLP-1 Patients

Anesthesiologists have several techniques and strategies available to manage the aspiration risk in GLP-1 patients. Understanding these approaches helps patients appreciate the safety measures in place and engage in informed discussions with their anesthesia provider.

Rapid Sequence Intubation (RSI)

RSI is the primary anesthetic technique used for patients considered to be at elevated aspiration risk. Unlike standard anesthesia induction, where the anesthesiologist may gently ventilate the patient via face mask before placing the breathing tube, RSI involves a rapid transition from consciousness to secured airway with minimal time during which the unprotected airway is at risk.

The RSI sequence typically involves: thorough pre-oxygenation (breathing 100% oxygen for 3-5 minutes to build an oxygen reserve), administration of a fast-acting induction agent (propofol or etomidate), immediate administration of a fast-acting neuromuscular blocker (succinylcholine or rocuronium at intubating doses), avoidance of positive-pressure mask ventilation (to prevent gastric insufflation), and immediate direct laryngoscopy and endotracheal intubation within 45-90 seconds of induction.

Optional adjuncts to RSI include cricoid pressure (gentle pressure applied to the cricoid cartilage in the neck to compress the esophagus against the vertebral body, theoretically preventing passive regurgitation), suction equipment immediately available at the head of the bed, and a head-up or ramped position to reduce passive reflux.

Awake Intubation

For patients with both a suspected full stomach and a difficult airway (common in obese patients), the anesthesiologist may choose to perform an awake fiberoptic intubation. In this technique, the patient remains conscious (with local anesthesia to the airway and mild sedation) while the anesthesiologist uses a flexible fiberoptic scope to guide the breathing tube into the trachea. Once the airway is secured with the breathing tube in place, general anesthesia is induced. This approach maintains the patient protective airway reflexes throughout the intubation process, eliminating the aspiration-vulnerable period entirely.

Laryngeal Mask Airway (LMA) Considerations

The laryngeal mask airway (LMA) is a supraglottic airway device commonly used for shorter or less invasive procedures. Unlike an endotracheal tube, the LMA sits above the glottis (the vocal cord opening) rather than passing through it. While LMAs are convenient and less invasive, they do not provide the same degree of airway protection against aspiration as an endotracheal tube. For GLP-1 patients with concern for retained gastric contents, most anesthesiologists prefer endotracheal intubation over LMA placement to maximize airway protection. Second-generation LMAs with gastric drainage channels provide some additional protection and may be acceptable in lower-risk situations.

Post-Operative Airway Management

The aspiration risk does not end when surgery is complete. Extubation (removal of the breathing tube) is another vulnerable period during which protective reflexes may still be impaired by residual anesthetic effects. For GLP-1 patients, the anesthesiologist may take extra precautions during extubation, including ensuring the patient is fully awake and following commands before removing the tube, positioning the patient on their side (lateral decubitus) during emergence to allow any regurgitated material to drain out of the mouth rather than into the airway, having suction immediately available, and considering leaving the breathing tube in place slightly longer than usual to ensure complete return of protective reflexes.

13. Resuming GLP-1 Medications After Surgery

The timing and approach to restarting GLP-1 medications after surgery is an important consideration that affects both surgical recovery and long-term treatment continuity. There is no universal guideline for post-operative GLP-1 resumption, and the decision involves balancing several factors.

General Principles for Resumption

The primary prerequisite for resuming GLP-1 therapy after surgery is adequate oral intake. The patient must be tolerating solid foods and drinking adequate fluids without significant nausea or vomiting before restarting a medication known to cause GI side effects and delayed gastric emptying. For most procedures, this means waiting until the patient is eating regular meals and maintaining hydration independently.

For minor outpatient procedures (short general anesthetic, quick recovery), patients may be able to resume their GLP-1 medication the day after surgery, provided they are eating and drinking normally. For moderate procedures (laparoscopic surgery, orthopedic procedures), resumption is typically feasible within 2-5 days when normal diet is tolerated. For major abdominal surgery (bowel resection, major hernia repair, bariatric surgery), resumption should wait until bowel function has fully returned, which may take 3-7 days or longer. Post-operative ileus (temporary paralysis of bowel function after abdominal surgery) is common and would be worsened by the addition of a GLP-1 medication that further slows GI motility.

Dose Resumption Strategy

If the GLP-1 medication has been held for 2 weeks or less, most patients can resume at their previous dose without retitrating. If held for 2-4 weeks, consider restarting at one dose level below the maintenance dose (e.g., restart at 0.5 mg if maintenance dose was 1 mg for semaglutide) and increasing after 2-4 weeks. If held for more than 4 weeks, retitration from the starting dose may be advisable to minimize GI side effects upon resumption. The longer the drug-free interval, the more likely the patient will experience GI side effects similar to initial therapy when restarting, as the tolerance that developed during chronic therapy may have waned.

Coordination with Diabetes Management

For diabetic patients, the transition back to GLP-1 therapy should be coordinated with the discontinuation of any temporary insulin coverage that was started during the perioperative period. As the GLP-1 medication takes effect (reaching steady-state levels after approximately 4-5 weeks of weekly dosing), insulin requirements will decrease and insulin doses should be reduced accordingly to prevent hypoglycemia. This transition is best managed by the patient endocrinologist or primary care provider with input from the surgical team.

14. Bariatric Surgery and GLP-1: Before and After

The relationship between GLP-1 medications and bariatric surgery is bidirectional and clinically important. Many patients considering bariatric surgery are currently on GLP-1 therapy for obesity, and an increasing number of bariatric patients are using GLP-1 medications after surgery for weight regain prevention.

GLP-1 Use Before Bariatric Surgery

Many bariatric surgeons prescribe GLP-1 medications as part of a pre-operative weight loss program. Losing 5-10% of body weight before bariatric surgery reduces liver size (making laparoscopic access easier and safer), decreases surgical risk, and demonstrates the patient commitment to the weight management process. Semaglutide and tirzepatide are particularly effective for this purpose due to their strong weight loss efficacy.

The pre-operative GLP-1 hold for bariatric surgery follows the same ASA guidelines as for other procedures, with some surgeons preferring a longer hold (2-3 weeks) due to the nature of abdominal surgery and the desire for completely normal gastric function during the procedure. The surgical team will provide specific instructions.

GLP-1 Use After Bariatric Surgery

The use of GLP-1 medications after bariatric surgery is an evolving area of practice. After sleeve gastrectomy or gastric bypass, the altered GI anatomy changes the pharmacological space significantly. Endogenous GLP-1 levels are already markedly elevated after Roux-en-Y gastric bypass due to rapid nutrient delivery to the distal small bowel (the ileal brake effect), raising questions about the additional benefit of exogenous GLP-1 administration.

However, clinical experience and emerging evidence suggest that GLP-1 medications can be effective for patients who experience weight regain after bariatric surgery - a phenomenon that affects 20-30% of bariatric patients over 5-10 years. Post-bariatric GLP-1 therapy may re-engage appetite suppression mechanisms, provide additional glucose control for patients with recurrent diabetes, and support behavioral weight management efforts.

Important considerations for post-bariatric GLP-1 use include altered drug absorption after gastric bypass (particularly relevant for oral semaglutide), increased sensitivity to GI side effects in patients with a smaller stomach pouch, and the need for careful nutritional monitoring given the combined restrictive and appetite-suppressing effects.

15. Dental Procedures and GLP-1 Medications

Dental procedures represent a common scenario where GLP-1 patients need guidance on whether to modify their medication. The answer depends primarily on the type of anesthesia or sedation used during the procedure.

Local Anesthesia Only

For dental procedures performed under local anesthesia (lidocaine injections) without any sedation, GLP-1 medications do not need to be stopped. Local anesthesia does not suppress airway protective reflexes, and the aspiration risk is essentially zero. This includes routine cleanings, fillings, simple extractions, crown preparations, root canals, and most periodontal procedures. Patients can take their GLP-1 medication on schedule and proceed with the dental appointment normally.

Nitrous Oxide (Laughing Gas)

Nitrous oxide provides mild anxiolysis and analgesia but does not suppress protective airway reflexes at the concentrations used in dental practice (typically 30-50% mixed with oxygen). Most practitioners and guidelines do not consider nitrous oxide alone to be a reason to hold GLP-1 medications. However, if nitrous oxide is combined with additional sedative medications (oral benzodiazepines, for example), the level of sedation may be sufficient to warrant GLP-1 precautions.

IV Sedation

Intravenous (IV) sedation is commonly used for wisdom tooth extractions, dental implant placement, and procedures in patients with dental anxiety. IV sedation can range from moderate (conscious sedation, where the patient can respond to verbal commands) to deep sedation (approaching general anesthesia). For moderate sedation, the aspiration risk is low but not zero, and the decision about GLP-1 management should be made by the sedation provider. For deep sedation, the GLP-1 holding guidelines should be followed as for general anesthesia.

General Anesthesia for Dental Procedures

Some dental procedures are performed under general anesthesia in a hospital or ambulatory surgery center. This includes complex oral surgery, multiple extractions in medically compromised patients, and dental procedures in patients who cannot cooperate with awake treatment. For these cases, full ASA guidelines for GLP-1 management apply, with the standard medication hold timelines and pre-operative assessment.

16. Endoscopy and Colonoscopy Considerations

Gastrointestinal endoscopy and colonoscopy are common procedures that GLP-1 patients may need, and the intersection of GLP-1 effects with endoscopic requirements creates specific management challenges.

Upper Endoscopy (EGD)

Upper endoscopy involves passing a flexible camera through the mouth into the esophagus, stomach, and duodenum. The procedure requires an empty stomach for two reasons: to allow adequate visualization of the stomach lining, and to reduce aspiration risk during sedation. GLP-1-induced delayed gastric emptying directly affects both of these requirements. Retained food in the stomach can obscure the view, prevent adequate biopsy sampling, and increase the risk of aspiration during sedation.

GLP-1 medications should be held before upper endoscopy following the same timelines as for surgery (7 days for weekly injections, 24 hours for daily formulations). Some gastroenterologists recommend a longer hold or a liquid diet for 24-48 hours before the procedure to optimize stomach visualization. If residual food is found despite standard preparation, the endoscopist may need to abort the procedure and reschedule after a longer drug-free interval.

Colonoscopy

Colonoscopy requires thorough bowel preparation to allow visualization of the colon lining. GLP-1 medications can impair bowel preparation quality through two mechanisms: delayed gastric emptying means the preparation solution moves through the GI tract more slowly, and the overall slowing of GI transit can result in incomplete colon cleansing. Studies have documented higher rates of inadequate bowel preparation in patients on GLP-1 medications.

Recommendations for colonoscopy preparation in GLP-1 patients include holding the GLP-1 medication for at least 7 days before the procedure (some gastroenterologists recommend 2 weeks), considering a split-dose preparation protocol (half the prep the evening before, half the morning of the procedure), starting a low-residue diet 3-5 days before the procedure (rather than the standard 1-2 days), transitioning to a clear liquid diet 24-48 hours before the prep begins, and being prepared for the possibility that the prep may need to be repeated if initial visualization is inadequate.

Additionally, colonoscopy typically involves moderate sedation (propofol or midazolam/fentanyl), which carries aspiration risk. The standard GLP-1 hold guidelines for sedation procedures should be followed.

Capsule Endoscopy

Capsule endoscopy involves swallowing a small camera capsule that photographs the small bowel as it passes through. GLP-1-induced delayed gastric emptying can cause the capsule to remain in the stomach longer than expected, potentially exhausting the battery before it reaches the areas of interest in the small bowel. Some practitioners recommend holding GLP-1 medications before capsule endoscopy and using prokinetic agents (metoclopramide, erythromycin) to help with gastric transit of the capsule.

17. Cosmetic Surgery and GLP-1 Medications

The rapid increase in GLP-1 medication use for weight loss has created a parallel surge in patients seeking cosmetic surgery after significant weight loss. Procedures such as abdominoplasty (tummy tuck), body contouring, brachioplasty (arm lift), thigh lift, and face/neck lift are increasingly performed on patients who have achieved substantial weight loss with semaglutide, tirzepatide, or other GLP-1 agents. This convergence of GLP-1 therapy and cosmetic surgery creates specific considerations for both patients and providers.

Timing of Cosmetic Surgery After Weight Loss

Most plastic surgeons recommend waiting until weight has been stable for at least 3-6 months before performing body contouring surgery. This ensures that the patient has reached their weight loss plateau and that the surgical results will be durable. For GLP-1 patients, this raises the question of whether to continue the medication during this stabilization period (which may help prevent weight regain) or to stop it before surgery (which the ASA guidelines recommend).

The practical approach most commonly taken is to continue GLP-1 therapy during the weight stabilization period, then hold the medication per ASA guidelines for the 7 days before surgery. After surgery, GLP-1 therapy is resumed once the patient is eating and drinking normally, with the goal of maintaining the weight loss achieved before surgery.

Specific Cosmetic Procedure Considerations

Abdominoplasty and body contouring procedures typically require general anesthesia and involve abdominal manipulation that can exacerbate post-operative nausea and ileus. The GLP-1 hold before these procedures is particularly important, and surgeons may recommend extending the hold to 2-3 weeks. Post-operative resumption should wait until the patient has full return of bowel function and is tolerating a normal diet, which may take 5-10 days after major body contouring.

Liposuction can sometimes be performed under local anesthesia with tumescent technique, in which case GLP-1 holds may not be necessary. However, if general anesthesia or deep sedation is used, standard guidelines apply. Breast augmentation, reduction, and lift procedures under general anesthesia require standard GLP-1 management. Face and neck lifts typically use general anesthesia or deep sedation, requiring standard holds.

Nutritional Considerations for Cosmetic Surgery on GLP-1

Patients who have undergone significant weight loss on GLP-1 therapy may have nutritional deficiencies that affect surgical healing. Protein intake is particularly important for tissue repair and wound healing, and GLP-1-induced appetite suppression may result in suboptimal protein consumption. Pre-operative nutritional optimization - including ensuring adequate protein intake (1.2-1.5 g/kg/day), correcting any vitamin or mineral deficiencies (especially vitamin D, iron, and zinc), and maintaining adequate caloric intake - is recommended for 2-4 weeks before elective cosmetic surgery.

18. Complete Pre-Operative Checklist for GLP-1 Patients

Checklist consolidates all the key actions patients should take when preparing for surgery while on GLP-1 therapy. Print this list or save it to your phone for reference as you prepare.

4-6 Weeks Before Surgery

• Inform your GLP-1 prescriber that you have surgery scheduled - discuss when to stop and how to manage diabetes/weight during the hold period
• Inform your surgeon that you are on a GLP-1 medication at your pre-operative consultation
• Ask your surgeon what type of anesthesia will be used (general, regional, or sedation)
• Begin documenting your GLP-1 injection dates if not already doing so
• Optimize nutrition - ensure adequate protein, vitamins, and mineral intake for surgical healing
• If diabetic, establish a perioperative glucose management plan with your provider

2-3 Weeks Before Surgery

• Confirm the exact date to stop your GLP-1 medication with your surgical team
• Obtain any temporary diabetes medications (insulin, blood glucose monitor) if prescribed
• Begin a blood sugar monitoring log if diabetic
• Stock up on clear liquids and easy-to-digest foods for the days before surgery
• Complete any required pre-operative testing (blood work, ECG, imaging)

7-10 Days Before Surgery (for weekly GLP-1 injections)

• Take your LAST GLP-1 injection dose at least 7 days before surgery - skip the next scheduled dose
• Record the exact date and time of your last injection
• Begin any temporary diabetes medication adjustments as directed by your provider
• Monitor blood sugar 2-4 times daily if diabetic
• Continue all other medications unless specifically instructed to stop

1-2 Days Before Surgery

• Follow your surgical team specific dietary instructions (some may recommend liquids only for 24-48 hours)
• Begin standard pre-operative fasting (NPO after midnight for morning surgery, or as instructed)
• Clear liquids are usually permitted up to 2 hours before arrival time - confirm with your team
• Prepare your medication list including GLP-1 name, dose, and date of last injection
• Review which other medications to take or hold on the morning of surgery
• Avoid NSAIDs (ibuprofen, naproxen) unless cleared by your surgeon

Day of Surgery

• Confirm NPO compliance - nothing to eat or drink after the instructed time
• Take only medications approved by your surgical team with a small sip of water
• Bring your medication list and the date of your last GLP-1 dose
• Tell the pre-operative nurse about your GLP-1 medication and last dose date
• Tell the anesthesiologist directly about your GLP-1 use
• Report any current GI symptoms (nausea, bloating, feeling of fullness)
• Ask about gastric ultrasound if you have concerns about stomach emptying
• Inform the team about any episodes of vomiting or difficulty eating in recent days

After Surgery

• Do not restart GLP-1 until you are tolerating solid foods and adequate fluids
• Follow your provider guidance on dose resumption (same dose or retitrate)
• Monitor blood sugar closely if diabetic during the transition back to GLP-1 therapy
• Discontinue temporary insulin when GLP-1 medication reaches therapeutic levels
• Report any unusual GI symptoms, vomiting, or inability to eat to your surgical team
• Attend all scheduled post-operative follow-up appointments
• Resume normal GLP-1 dosing schedule once cleared by your provider

19. Frequently Asked Questions

19b. Pediatric and Adolescent GLP-1 Patients and Surgery

With the FDA approval of semaglutide (Wegovy) for adolescents aged 12 and older with obesity, and tirzepatide (Zepbound) following a similar trajectory, the perioperative management of GLP-1 medications is now relevant to younger patient populations. Pediatric and adolescent patients present unique considerations that differ from adult management in several important ways.

Prevalence and Context

Childhood and adolescent obesity affects approximately 20% of children in the United States, with severe obesity (BMI at or above 120% of the 95th percentile) increasingly common. The approval of GLP-1 medications for adolescents has expanded treatment options beyond lifestyle intervention and bariatric surgery. As more adolescents are prescribed these medications, surgical encounters during GLP-1 therapy become more frequent - whether for appendectomy, orthopedic procedures from sports injuries, tonsillectomy, or other conditions common in this age group.

Physiological Differences

Children and adolescents have several physiological differences from adults that affect perioperative GLP-1 management. Gastric emptying is generally faster in children than in adults, which may mean that the delayed gastric emptying effect of GLP-1 medications brings their emptying rate closer to (but not necessarily exceeding) normal adult rates rather than causing the same degree of delay seen in adults. However, this has not been specifically studied, and the ASA guidelines should be followed regardless.

Children are more susceptible to dehydration than adults due to their higher surface-area-to-body-weight ratio, higher metabolic rate, and smaller fluid reserves. The GLP-1-related GI side effects that can cause dehydration in adults may have more rapid and severe consequences in younger patients. Extra attention to pre-operative hydration is warranted.

Adolescents may have less understanding of and adherence to complex pre-operative instructions compared to adults. Clear, age-appropriate communication about the importance of medication holds and fasting is essential. Involving parents or guardians in the pre-operative preparation process helps ensure compliance.

Communication and Consent

For adolescent GLP-1 patients, pre-operative communication should involve the patient, parent(s)/guardian(s), the prescribing provider, the surgeon, and the anesthesiologist. The adolescent should be educated about why their medication is being temporarily stopped and the importance of following fasting instructions. Parents should be briefed on monitoring for GI symptoms, ensuring hydration, and managing any diabetes medications during the hold period.

Some adolescents may be sensitive about disclosing their GLP-1 medication use, as it may relate to body image concerns or weight stigma. Healthcare providers should approach these conversations with sensitivity and privacy, avoiding discussing weight or medication status in front of other patients or non-essential staff.

Anesthesia Considerations for Adolescent GLP-1 Patients

Pediatric anesthesiologists are well-versed in managing aspiration risk, as children in general have different fasting guidelines than adults and are frequently managed as higher-risk patients. The addition of GLP-1 therapy does not fundamentally change the approach but adds an additional risk factor to consider. The same options available for adults - rapid sequence intubation, gastric ultrasound, medication timing adjustments - are available and appropriate for adolescent patients.

Fasting guidelines for adolescents are the same as for adults (6-8 hours for solids, 2 hours for clear liquids). The same modified fasting considerations that apply to adult GLP-1 patients (potential liquid-only diet before surgery, extended fasting) can be applied to adolescents with appropriate nutritional monitoring to avoid prolonged caloric restriction in a growing patient.

19c. GLP-1 Medications and Obstetric Surgery (Cesarean Section)

While GLP-1 receptor agonists are generally not recommended during pregnancy and should be discontinued at least 2 months before a planned pregnancy (due to insufficient safety data in human pregnancy and teratogenicity signals in animal studies), unplanned pregnancies can occur during GLP-1 therapy. Additionally, the long half-life of weekly injections like semaglutide means the drug may still be present in the body for weeks after discontinuation. Understanding the obstetric surgical implications is therefore clinically relevant.

Pregnancy and GLP-1 Pharmacokinetics

Semaglutide has a half-life of approximately 7 days, meaning it takes approximately 5 half-lives (35 days or about 5 weeks) for the drug to be virtually eliminated from the body. Novo Nordisk (the manufacturer) recommends discontinuing semaglutide at least 2 months before a planned pregnancy. However, for unplanned pregnancies discovered while on semaglutide, the drug should be stopped immediately and the patient referred for obstetric care.

If a patient on semaglutide requires an emergency cesarean section or other obstetric surgery while the drug is still in their system, the gastric emptying considerations are compounded by the already-delayed gastric emptying of pregnancy itself. Pregnancy hormones (progesterone) relax smooth muscle throughout the GI tract, and the gravid uterus mechanically compresses the stomach - both of which slow gastric emptying. Adding GLP-1 effects on top of pregnancy-related gastric slowing creates a significantly elevated aspiration risk.

Management of Obstetric Patients with Recent GLP-1 Exposure

Obstetric anesthesia already treats all pregnant patients beyond approximately 16-20 weeks gestation as full-stomach patients, employing rapid sequence intubation for general anesthesia and preferring regional anesthesia (spinal or epidural) whenever possible. For patients with recent GLP-1 exposure, regional anesthesia should be strongly preferred for cesarean delivery, as it avoids airway manipulation entirely. If general anesthesia is required (emergency situations, failed regional block, patient contraindications to regional), standard obstetric RSI technique is used with the additional awareness of GLP-1-enhanced gastric delay.

Obstetric teams should be informed about any recent GLP-1 use during prenatal care so that delivery planning can account for the additional aspiration risk. This information should be documented prominently in the obstetric chart and communicated to the anesthesia team at the time of any surgical delivery.

19d. Institutional Protocols and Emerging Standards

As the perioperative management of GLP-1 medications becomes a standard component of surgical care, healthcare institutions are developing formal protocols to ensure consistent, safe management. Understanding how these institutional approaches are evolving helps patients know what to expect and what to ask about when scheduling surgery.

Pre-Operative Screening Protocols

Many hospitals and ambulatory surgery centers have added GLP-1 medication screening to their standard pre-operative questionnaires. Patients may be asked specifically whether they take any medications for weight loss or diabetes that are given by injection, whether they take semaglutide, tirzepatide, liraglutide, or similar medications, when they took their last dose, and whether they have any current GI symptoms including nausea, vomiting, bloating, or abdominal pain.

Some institutions have implemented electronic health record (EHR) alerts that flag patients with active GLP-1 prescriptions when they are scheduled for surgical procedures. These alerts prompt the scheduling team to verify that the patient has received appropriate instructions about when to hold the medication and trigger a pre-operative anesthesia consultation for higher-risk patients.

Day-of-Surgery Protocols

Institutional day-of-surgery protocols for GLP-1 patients typically include a standardized assessment by the pre-operative nursing team (confirming medication hold, assessing GI symptoms, documenting last dose date), anesthesiologist notification and assessment (reviewing GLP-1 status, determining anesthesia plan, considering gastric ultrasound), availability of gastric ultrasound equipment in the pre-operative area, documentation of the GLP-1 management plan in the anesthesia record, and availability of RSI medications and equipment as a contingency.

Post-Operative Protocols

Post-operative protocols address when and how to restart GLP-1 medications, including standardized criteria for GLP-1 resumption (e.g., tolerating solid food, adequate oral fluid intake, no significant nausea or vomiting), guidance on dose resumption strategy (same dose versus retitration), coordination with the patient endocrinologist or primary care provider for diabetes medication management, and documentation of the GLP-1 restart plan in the discharge instructions.

Multi-Disciplinary Coordination

Effective perioperative GLP-1 management requires coordination between multiple healthcare providers: the prescribing provider (who manages the medication hold and alternative diabetes therapy), the surgeon (who schedules the procedure and communicates with the patient), the pre-operative assessment team (who screens for GLP-1 use and GI symptoms), the anesthesiologist (who makes the final risk assessment and anesthesia plan), and the post-operative care team (who manages the medication restart). Clear communication pathways between these providers are essential, and patients serve as an important link by ensuring that each team member is aware of their GLP-1 use.

Professional Society Updates and Future Guidance

The medical community continues to refine its approach to perioperative GLP-1 management. Professional societies including the ASA, the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the American Association of Nurse Anesthesiology (AANA), and international counterparts are actively reviewing new evidence and updating guidance. Key areas of active investigation include the optimal duration of GLP-1 hold for different medication types and doses, the role of gastric ultrasound as a decision-making tool versus a universal screening test, whether extended fasting protocols are needed in addition to medication holds, the safety of proceeding with surgery using RSI when GLP-1 has not been adequately held, and the development of pharmacological tools (prokinetic agents) to accelerate gastric emptying in GLP-1 patients who need urgent surgery.

Patients should be aware that recommendations may evolve as new data becomes available, and should always follow the most current guidance from their surgical team rather than relying solely on older information.

GLP-1 Medications and Post-Operative Wound Healing

A question that many patients and surgeons have is whether GLP-1 medications affect wound healing after surgery. The relationship between these drugs and tissue repair is an area of active research, and the current evidence is generally reassuring, though some nuances are worth understanding.

On the positive side, GLP-1 medications improve several metabolic parameters that are known to support healthy wound healing. Better blood sugar control, reduced systemic inflammation, and improved cardiovascular function can all contribute to a healing environment that is more favorable than what many patients with obesity or type 2 diabetes might otherwise experience. Some preclinical studies in animal models have even suggested that GLP-1 receptor activation may have direct positive effects on tissue repair and angiogenesis, which is the formation of new blood vessels that supply healing tissue with oxygen and nutrients.

On the other hand, the caloric restriction and reduced protein intake that sometimes accompany GLP-1 treatment can potentially impair wound healing if nutritional status is not adequately managed. Protein is essential for tissue repair, and patients who are eating significantly less than usual may not be getting enough of the amino acids their body needs to heal effectively after surgery. This is one reason why many surgeons recommend optimizing protein intake in the weeks before and after a planned procedure.

The bottom line is that GLP-1 medications themselves do not appear to impair wound healing in most patients, but the dietary changes that accompany their use may need to be addressed in the perioperative period. Talk to your surgical team about nutritional optimization before your procedure, and consider working with a dietitian to ensure you are meeting your protein and micronutrient needs during the recovery period.

19e. Psychological and Practical Considerations for GLP-1 Patients Facing Surgery

Beyond the medical and pharmacological considerations, GLP-1 patients facing surgery often experience unique psychological and practical challenges that deserve attention. Addressing these issues proactively can improve the overall surgical experience and treatment adherence.

Anxiety About Stopping the Medication

Many patients on GLP-1 medications for weight loss experience significant anxiety about temporarily stopping their medication before surgery. The fear of weight regain, loss of appetite control, and return of food cravings can be psychologically distressing, particularly for patients who have struggled with weight for years and are finally experiencing success with GLP-1 therapy. This anxiety is understandable but should not lead patients to conceal their medication use from their surgical team or to take their medication closer to surgery than recommended.

Healthcare providers should acknowledge these concerns empathetically. A brief 1-2 week medication hold is very unlikely to result in significant weight regain, and the long half-life of weekly GLP-1 medications means that appetite-suppressing effects persist for days after the last dose. Patients can be reassured that their weight loss progress is not at risk from a short surgical hold, and that resuming the medication after surgery will restore the full therapeutic effect.

Practical strategies to manage anxiety include maintaining the eating habits and portion sizes established while on the medication (the behavioral patterns are valuable independent of the drug effect), focusing on protein-rich foods that promote satiety naturally, planning meals and snacks in advance for the medication-free period to avoid impulsive eating, engaging in light physical activity (walking, stretching) to the extent permitted by the surgical condition, and staying in contact with their weight management provider for support during the hold period.

Fear of Blood Sugar Loss of Control

Diabetic patients may experience anxiety about losing blood sugar control during the medication hold. This concern is valid - blood glucose levels may rise without the GLP-1 component of their diabetes regimen - but it can be managed with proactive planning. Working with the endocrinologist or primary care provider to develop a specific perioperative glucose management plan well before the surgery date provides both practical and psychological reassurance. Having a concrete plan (which medications to adjust, when to check blood sugar, what insulin doses to use if levels rise) reduces uncertainty and helps patients to manage their diabetes actively during the medication-free period.

Disclosure Concerns

Some patients are reluctant to disclose their GLP-1 medication use due to stigma around weight management medications or weight-related health conditions. This reluctance can be particularly acute in patients who have not shared their GLP-1 use with family members or friends who may be accompanying them to the surgical appointment. Healthcare providers should create a safe environment for disclosure by asking about GLP-1 medications in private, normalizing their use (these are widely prescribed, evidence-based medications), and emphasizing that disclosure is a safety issue, not a judgment.

Patients should understand that withholding this information from their anesthesiologist is genuinely dangerous - the aspiration risk from undisclosed GLP-1 use during general anesthesia is a real and potentially life-threatening concern. No matter how uncomfortable the disclosure may feel, it is essential for safe surgical care.

Financial and Insurance Considerations

The temporary hold of a GLP-1 medication before surgery can create financial considerations. Weekly injectable semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are expensive medications, and patients on some insurance plans may have concerns about wasted doses during the hold period. For weekly injections, the missed dose represents one weeks supply. Patients should not "double up" on their next dose after surgery to compensate for the missed dose - this is both unnecessary and potentially harmful.

For patients with limited medication supply or high copayments, the timing of the medication hold can be coordinated with the prescription fill schedule to minimize waste. For example, a patient might time their last pre-surgical dose to coincide with the end of a monthly supply rather than the beginning, so the missed dose does not result in an unused pen that expires.

Planning for Recovery While Off Medication

Patients should plan for the post-surgical period during which they will be off their GLP-1 medication. This includes having a support system in place for meal preparation (as the patient may not be able to cook during recovery), stocking the kitchen with healthy, easy-to-prepare foods that align with their weight management goals, having a plan for gentle physical activity resumption as cleared by the surgeon, scheduling a follow-up with their GLP-1 prescriber within 1-2 weeks after surgery to coordinate medication restart, and maintaining a food and symptom diary during the off-medication period to share with their provider at follow-up.

The perioperative period can actually be an informative time for patients and providers to understand how the patient metabolic parameters (blood sugar, appetite, weight) respond to GLP-1 withdrawal, which can inform long-term treatment planning.

19f. Quick Reference Summary Tables

19g. Real-World Scenarios and Case-Based Guidance

Understanding the theory behind GLP-1 perioperative management is important, but many patients benefit from seeing how the principles apply to realistic clinical scenarios. This section presents common situations patients may encounter and explains the recommended approach for each.

Scenario 1: Planned Knee Replacement in a Patient on Ozempic

A 58-year-old woman has been on semaglutide (Ozempic) 1mg weekly for 10 months, losing 35 pounds. She is scheduled for a right total knee replacement under general anesthesia in 6 weeks. She also takes metformin 1000mg twice daily and lisinopril 20mg daily for blood pressure. Her HbA1c is 6.8% and her BMI is 34.

Recommended approach: At her pre-operative consultation, she should inform the surgical team about her Ozempic use. She should continue Ozempic on her regular schedule until her last injection at least 7 days before surgery. Since she injects on Fridays and surgery is on a Thursday, she should take her injection on the Friday that falls 13 days before surgery (giving a 13-day hold) and skip the Friday injection that would fall 6 days before surgery (which would be too close). She should hold metformin starting 48 hours before surgery per standard diabetes guidelines. Her lisinopril can typically be continued but should be confirmed with the anesthesia team. She should discuss whether regional anesthesia (spinal or nerve block) is possible for her knee replacement, as this would eliminate the airway aspiration concern entirely. Blood sugar monitoring should increase to 3-4 times daily during the Ozempic hold period, and her provider may prescribe sliding-scale insulin if glucose levels rise above 200 mg/dL.

Scenario 2: Urgent Cholecystectomy in a Patient Who Took Wegovy 3 Days Ago

A 42-year-old man on semaglutide (Wegovy) 2.4mg weekly for weight management presents to the emergency department with acute cholecystitis (gallbladder inflammation). He took his weekly Wegovy injection 3 days ago. The surgeon recommends laparoscopic cholecystectomy within 24-48 hours (urgent but not immediately life-threatening).

Recommended approach: This is a semi-urgent situation where delaying surgery carries risks (gallbladder perforation, sepsis) but immediate surgery is not required. The anesthesiologist should be notified about the recent Wegovy dose. Options include: proceeding with surgery using rapid sequence intubation and full-stomach precautions; performing a gastric ultrasound before induction to assess stomach contents; recommending a clear liquid diet for the 24-48 hours before surgery; and placing a nasogastric tube in the pre-operative area to decompress the stomach if ultrasound shows significant contents. In this case, most anesthesiologists would proceed with surgery using RSI, as the risk of delaying cholecystectomy outweighs the aspiration risk when appropriate precautions are taken.

Scenario 3: Colonoscopy Screening in a Patient on Mounjaro

A 50-year-old woman on tirzepatide (Mounjaro) 10mg weekly for type 2 diabetes is due for her first routine screening colonoscopy. She has been on tirzepatide for 6 months with excellent glucose control (HbA1c 6.5%) and 28 pounds of weight loss.

Recommended approach: She should discuss the colonoscopy timing with both her gastroenterologist and her prescribing provider. The tirzepatide should be held for at least 7 days before the colonoscopy, with some gastroenterologists recommending a 14-day hold for optimal bowel preparation quality. She should transition to a low-residue diet 3-5 days before the prep and a clear liquid diet 24-48 hours before beginning the bowel preparation. A split-dose prep protocol is preferred. Her diabetes medications may need temporary adjustment during the hold period - her provider might prescribe a DPP-4 inhibitor (sitagliptin) as a bridge or add sliding-scale insulin if glucose levels rise. She should resume tirzepatide at her usual dose after the colonoscopy when she is eating and drinking normally, typically the same day or next day for this outpatient procedure.

Scenario 4: Emergency Appendectomy in an Adolescent on Wegovy

A 15-year-old boy on semaglutide (Wegovy) 1.7mg weekly for obesity presents with acute appendicitis requiring emergency laparoscopic appendectomy. His last Wegovy injection was 2 days ago. He ate a hamburger and fries approximately 6 hours before presenting to the emergency department.

Recommended approach: This is a true surgical emergency that cannot be delayed. The anesthesiologist should be informed about both the recent Wegovy dose and the recent meal. The patient should be managed as a full-stomach patient with rapid sequence intubation. A nasogastric tube may be placed before induction to attempt gastric decompression, though solid food may not be easily suctioned. Cricoid pressure should be applied during the RSI sequence. Post-intubation, the orogastric tube should be placed under direct vision to further decompress the stomach. The surgery should proceed without delay - appendicitis can progress to perforation and peritonitis, which carries far greater risk than the aspiration risk managed by RSI technique.

Scenario 5: Cosmetic Abdominoplasty After Major Weight Loss on Semaglutide

A 45-year-old woman has lost 80 pounds over 14 months on semaglutide (Wegovy 2.4mg weekly) and has maintained a stable weight for 4 months. She wants abdominoplasty to address excess skin. She does not have diabetes. She wants to continue semaglutide after surgery to prevent weight regain.

Recommended approach: Her weight should be stable for at least 3-6 months before scheduling surgery (she meets this criterion). Given the higher dose of semaglutide and the abdominal nature of the surgery, a 2-3 week hold may be preferred over the minimum 7-day hold. She should transition to a nutrient-dense, protein-rich diet (1.2-1.5 g protein/kg/day) for 2-4 weeks before surgery to optimize healing capacity. Pre-operative labs should include albumin and pre-albumin to assess nutritional status. Standard fasting guidelines apply with consideration for a 24-48 hour liquid-only diet before surgery. After abdominoplasty, she should wait until bowel function returns and she is eating normally before resuming Wegovy - typically 5-10 days for this procedure. She may restart at 1.7mg (one dose level down) for 2-4 weeks before returning to 2.4mg, given the approximately 3-4 week medication-free period.

Scenario 6: Patient Who Forgot to Stop Liraglutide Before Surgery

A 62-year-old man on liraglutide (Saxenda) 3mg daily arrives for an elective laparoscopic inguinal hernia repair. During the pre-operative interview, he mentions he took his liraglutide injection this morning - he forgot the instruction to hold it. His surgery is scheduled to start in 2 hours.

Recommended approach: Since liraglutide is a daily injection with a half-life of approximately 13 hours, the drug level is at or near its peak. The anesthesiologist should assess the patient for GI symptoms (nausea, bloating, fullness). A gastric ultrasound should be performed to assess stomach contents. If the stomach is empty or contains only a small volume of clear liquid, the surgeon and anesthesiologist may decide to proceed with RSI technique. If significant solid or liquid contents are found, the case should be delayed (it is elective) and rescheduled with proper medication hold. The patient should be re-educated about the importance of holding the medication and given written instructions for the rescheduled date.

Scenario 7: Wisdom Teeth Extraction Under IV Sedation

A 22-year-old college student on liraglutide (Saxenda) 1.8mg daily for weight management is scheduled for four impacted wisdom teeth extraction under IV sedation with an oral surgeon. She asks whether she needs to stop her medication.

Recommended approach: Since the procedure involves IV sedation (which can range from moderate to deep sedation), she should hold her liraglutide for at least 24 hours before the procedure. She should not take her injection the morning of the procedure. She should follow standard fasting guidelines provided by the oral surgeon. The oral surgeon and sedation team should be informed about her liraglutide use so they can have appropriate airway management equipment available (suction, emergency intubation supplies). If moderate sedation is planned (patient remains responsive to verbal commands), the aspiration risk is low. If deep sedation is planned, the team should be prepared for full-stomach management if needed. She can resume liraglutide the day after the procedure when she is tolerating fluids.

These scenarios illustrate the practical application of the principles discussed throughout this guide. The key themes are consistent: communicate with your surgical team, follow medication hold guidelines, and never delay truly urgent or emergent surgery because of GLP-1 concerns.

19h. Patient Advocacy and Resources for Perioperative GLP-1 Management

Understanding the intersection of GLP-1 medications and surgical care can feel overwhelming, particularly for patients managing multiple health conditions simultaneously. This section provides guidance on advocating for yourself within the healthcare system and accessing resources that support safe perioperative care.

Being Your Own Advocate

Patients on GLP-1 medications bear an important responsibility in the perioperative period: ensuring that their medication status is communicated to every member of the surgical team. While healthcare systems have processes to capture this information, no system is perfect, and the consequences of a communication gap in this context can be serious. Proactive self-advocacy includes bringing a written medication list to every pre-operative appointment and to the hospital on the day of surgery; confirming verbally with each new healthcare provider you encounter (surgeon, anesthesiologist, nurse, physician assistant) that they are aware of your GLP-1 medication; asking questions about how your medication will be managed rather than assuming the team has a plan; requesting written pre-operative instructions specific to your GLP-1 medication if they are not provided automatically; and following up if instructions seem unclear, conflicting, or incomplete.

If you encounter a provider who seems unfamiliar with GLP-1 perioperative guidelines, you can politely reference the ASA 2023 consensus guidance and ask that an anesthesiologist be consulted for specific management recommendations. Healthcare providers appreciate informed patients who participate actively in their care, and asking about GLP-1 management demonstrates engaged, responsible health literacy.

Support from Your GLP-1 Prescriber

Your primary care provider, endocrinologist, or weight management specialist who prescribes your GLP-1 medication is a valuable ally during the perioperative period. They can communicate directly with your surgical team about the optimal medication hold strategy, provide a bridging diabetes management plan for the medication-free period, monitor your metabolic parameters (blood sugar, blood pressure, weight) during and after the hold, advise on the appropriate timing and dosing for medication resumption after surgery, and address your concerns about weight regain or blood sugar instability during the hold.

Schedule a specific appointment or phone call with your GLP-1 prescriber as soon as surgery is planned. Do not wait until the week before surgery to address medication management - early planning reduces stress and allows adequate time for any needed adjustments.

Medical Alert Identification

Given the growing recognition of GLP-1 perioperative risks, some patients may benefit from medical alert identification that includes their GLP-1 medication. Medical alert bracelets, necklaces, and digital ID cards can communicate this information to emergency medical personnel if the patient is unable to speak for themselves. While not strictly necessary for all GLP-1 patients, medical alert identification may be particularly valuable for patients who live alone and could experience a medical emergency requiring surgery, patients with communication barriers (language, cognitive impairment, hearing loss), patients on multiple high-risk medications where comprehensive medication awareness is critical, and patients traveling in areas where their regular medical records may not be accessible.

Modern medical alert services allow patients to maintain a detailed medication profile online that emergency responders can access via a unique identifier on the physical alert device. This ensures that up-to-date medication information is available even in emergency situations where the patient medical records from their home hospital are not accessible.

Preparing for Travel and Surgery Away from Home

Patients on GLP-1 medications who need surgery while traveling or at a facility distant from their regular providers face additional challenges. Pre-trip preparation includes carrying a current medication list (including GLP-1 name, dose, and prescriber contact information), keeping digital copies of relevant medical records accessible on a phone or cloud storage, ensuring travel insurance covers potential surgical complications, carrying enough GLP-1 medication for the trip plus a backup supply in case of delays, and knowing the nearest medical facilities at the travel destination.

If surgery becomes necessary while traveling, the patient should provide the treating team with their medication list, prescriber contact information, and date of last GLP-1 dose. The treating team can contact the patient regular provider for clinical context if needed. All GLP-1 perioperative principles discussed in this guide apply regardless of where the surgery takes place.

Staying Informed

The field of perioperative GLP-1 management is evolving rapidly, and recommendations may change as new evidence emerges. Patients can stay informed by asking their healthcare providers about any updates to GLP-1 surgical guidelines at regular appointments, checking the ASA website for updated guidance documents, following credible medical information sources that cover GLP-1 therapy developments, and discussing any new recommendations with their prescriber before their next scheduled procedure.

The most important resource, however, remains the relationship between the patient and their healthcare team. Open communication, mutual respect, and shared decision-making ensure that GLP-1 medications and surgery can coexist safely, allowing patients to benefit from both effective metabolic therapy and necessary surgical care.

Conclusion

Managing GLP-1 medications around surgery requires planning, communication, and adherence to evidence-based guidelines. The core message is straightforward: GLP-1 medications delay gastric emptying, which increases aspiration risk during anesthesia, so these medications should be held before elective surgery following ASA-recommended timelines. Weekly injections like semaglutide should be stopped at least 7 days before the procedure, and daily formulations at least 24 hours before.

However, the management goes beyond simply stopping a medication. Patients must communicate their GLP-1 use to every member of the surgical team, be aware of GI symptoms that may indicate ongoing gastroparesis-like effects, manage their diabetes or weight during the medication-free period, follow pre-operative fasting guidelines appropriate for their situation, and plan for medication resumption after surgery in coordination with their providers.

Emergency surgery can always proceed safely with appropriate anesthetic technique, and patients should never delay necessary medical care because of concerns about their GLP-1 medication. The surgical and anesthesia teams have multiple strategies - rapid sequence intubation, gastric ultrasound, nasogastric decompression - to manage the aspiration risk when GLP-1 medications cannot be stopped in advance.

As GLP-1 prescribing continues to grow and more patients require surgical procedures while on these medications, perioperative GLP-1 management protocols will continue to evolve. Patients who are informed, prepared, and proactive in communicating with their healthcare teams will have the safest possible surgical experiences.

This article is regularly updated as new guidelines and clinical evidence become available. Last reviewed and updated: March 25, 2026.